Purdue Pharma’s opioid overdose drug gets US regulator’s nod
US drugmaker Purdue Pharma’s injection to treat opioid overdose in adults and patients 12 years or older, got the country’s drug regulator’s approval.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
US drugmaker Purdue Pharma’s injection to treat opioid overdose in adults and patients 12 years or older, got the country’s drug regulator’s approval.
Switzerland’s Novartis AG has received accelerated approval from the USFDA for its drug to reduce elevated levels of proteins in the urine of.
Danish biotechnology company, Pharmacosmos A/S will buy US-based G1 Therapeutics Inc., for $405 million to expand its global commercial portfolio in haematology.
Servier Pharmaceuticals, the US arm of a French pharmaceutical company, got approval from the US drug regulator for a once-daily pill to treat.
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.
UK-based biopharmaceutical company, Adaptimmune Therapeutics Plc, got FDA approval for its cell therapy for treating a rare form of cancer.
The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.
Overdose of weight-loss drugs and dosing errors by patients and healthcare providers have led to adverse events, including hospitalisation, the USFDA warned.
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.
Novo Nordisk, has been denied approval for its type 1 diabetic medicine by the USFDA, according to the Danish drugmaker.